| Biomarker ID | 861 |
| PMID | 22302227 |
| Year | 2012 |
| Biomarker | stromal cell–derived factor 1α (SDF-1α) |
| Biomarker Basis | Expression Based |
| Biomolecule | Protein |
| Source | Plasma |
| Subjects | Humans |
| Regulation | Upregulated in Treatment Group (Treatment: 2,294 (1,775–2,671) Vs Control : 1,736 (1,577–1,842) ) |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | Pathways Include:-Binding of chemokines to chemokine receptors,Nuclear signaling by ErbB4,Intestinal immune network for IgA production,HIF-1 transcriptional activity in hypoxia, Interleukin-7 interactions in immune response |
| Experiment | ADT Treatment Vs No Treatment |
| Type of Biomarker | Predictive |
| Cohort | 37 ADT-naïve men with locally advanced or recurrent prostate cancer. Of those, 23 initiated ADT with a gonadotropin-releasing hormone (GnRH) agonist and 14 served as nontreatment controls. |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p=0.023 |
| Method Used | ELISA |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | CXCL12 |